Streetbeat News

Equity Actions

INBS

Intelligent Bio Solutions' stock is trading lower following the announcement of the exercise of previously issued warrants, resulting in $1.77 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:58 pm

BOWL

Bowlero has announced an extension and increase of its share repurchase program, replenishing the authorized repurchase amount to $200 million and removing the expiration date.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:36 pm

INBS

Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced the exercise of Series E Warrants issued on October 4, 2023, resulting in $1.77M in gross proceeds. The exercise involves 606,064 shares at $2.9232 each. Additionally, warrant holders will receive new Replacement Warrants for the same number of shares at $4.50 each, valid for five-and-a-half years. The funds are intended for working capital and general corporate purposes. Ladenburg Thalmann & Co. Inc. served as the placement agent.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 2:09 pm

RSKD

Riskified (NYSE:RSKD) has been analyzed by 4 analysts, showing a shift towards a more neutral stance in the last three months with an average 12-month price target of $5.00, down from $5.88. The company's financial indicators such as revenue growth, net margin, ROE, and ROA show positive performance, but it faces challenges in revenue growth compared to its peers. Riskified's low debt-to-equity ratio indicates a healthy balance between debt and equity.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 2:01 pm

EXPE

Expedia Group (NASDAQ:EXPE) received mixed ratings from 12 analysts, with a shift towards more bullish perspectives in recent evaluations. The average 12-month price target is now $164.00, up 27.13% from the previous $129.00, indicating a positive outlook. Analysts from firms like Oppenheimer, Goldman Sachs, and Mizuho have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Despite positive revenue growth, Expedia faces challenges in net margin, ROE, and ROA, but has a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 2:00 pm

PH

Analysts have mixed views on Parker Hannifin (NYSE:PH), with recent ratings showing a shift towards a more bullish stance. The average 12-month price target has been raised to $528.57, indicating a 7.3% increase from the previous target. Parker Hannifin's financial performance is strong, with notable revenue growth and net margin, but it faces challenges in ROA and higher debt levels. Analysts' actions and price target adjustments reflect their response to market conditions and company performance.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 2:00 pm

PROC

Procaps Group's new CEO, Jose Vieira, issued a letter to shareholders outlining his immediate focus on strengthening the company's financial position and cash management. He emphasized a commitment to transparency, innovation, and collaboration, aiming for consistent growth and profitability. Vieira plans to implement immediate actions to improve the financial situation in the short term and is developing a clear strategy for sustainable growth.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:53 pm

TGL

Treasure Global Inc's CEO, Sam Teo, purchased 1.17M shares of TGL at $0.0841 per share, signaling confidence in the company's future. This investment of $98,397 increases his stake to 5.11% of the voting shares. Teo's action aligns with TGL's strategic vision for growth and innovation in the technology sector.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:34 pm

CI

The Cigna Group (NYSE:CI) has initiated tender offers to purchase up to $2.25 billion in aggregate principal amount of its outstanding notes. This includes an 'Any and All Tender Offer' for its 3.50% Senior Notes due 2024 and Evernorth Health, Inc.'s 3.50% Senior Notes due 2024, and a 'Maximum Tender Offer' for various notes due between 2025 and 2030, with a maximum amount of $1,250,000,000. The offers are subject to terms and conditions detailed in the Offer to Purchase dated February 5, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:27 pm

LIVN

LivaNova PLC (NASDAQ:LIVN), a leading medical technology company, announced Vladimir A. Makatsaria as its new CEO and Board Director, effective March 1, 2024. Makatsaria, with a notable career at Johnson & Johnson MedTech, succeeds Bill Kozy, who remains Board Chair. This leadership transition is part of LivaNova's strategic plan for long-term growth.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:25 pm